68Ga-PSMA-11 PET显像定量转移性结直肠癌的摄取
研究对10例转移性结直肠癌患者行68Ga-PSMA-11 PET/CT显像以评估转移灶亲和性,其中8例病灶无亲和性,2例孤立转移灶亲和性极低;尽管结直肠癌新生血管表达PSMA,但无患者肿瘤亲和性足以考虑177Lu-PSMA-617肽受体放射性核素治疗。
要点
- 10例转移性结直肠癌患者接受68Ga-PSMA-11 PET/CT显像评估转移灶亲和性
- 8例病灶缺乏亲和性,2例孤立转移灶亲和性极低
- 无患者肿瘤亲和性足以考虑177Lu-PSMA-617肽受体放射性核素治疗
核心结论
- 尽管结直肠癌新生血管表达PSMA,但本组转移性结直肠癌患者中无人的肿瘤亲和性足以考虑177Lu-PSMA-617肽受体放射性核素治疗。
研究设计与样本
- 对10例转移性结直肠癌患者行68Ga-PSMA-11 PET/CT显像,评估转移灶亲和性。
主要发现
- 10例患者中8例病灶缺乏亲和性,2例孤立转移灶亲和性极低。
- 结直肠癌新生血管表达PSMA,但无患者肿瘤亲和性足以考虑177Lu-PSMA-617肽受体放射性核素治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
At diagnosis, 22% of colorectal cancer (CRC) patients have metastases, and 50% later develop metastasis. Peptide receptor radionuclide therapy (PRRT), such as 177Lu-PSMA-617, is used to treat metastatic prostate cancer. 177Lu-PSMA-617 targets prostate-specific membrane antigen (PSMA), a cell-surface protein enriched in prostate cancer and the neovasculature of other solid tumors, including CRC. We performed 68Ga-PSMA-11 PET/CT imaging of 10 patients with metastatic CRC to assess metastasis avidity. Eight patients had lesions lacking avidity, and 2 had solitary metastases exhibiting very low avidity. Despite expression of PSMA in CRC neovasculature, none of the patients exhibited tumor avidity sufficient to be considered for 177Lu-PSMA-617 PRRT.
引用
- Cuda TJ, Riddell AD, Liu C, et al. PET Imaging Quantifying 68Ga-PSMA-11 Uptake in Metastatic Colorectal Cancer. J Nucl Med. 2020. PMID: 32358088. doi:10.2967/jnumed.119.233312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。